IRIS
VENDITTI, ADRIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 69.075
EU - Europa 8.255
AS - Asia 7.518
SA - Sud America 1.263
AF - Africa 169
OC - Oceania 42
Continente sconosciuto - Info sul continente non disponibili 24
Totale 86.346
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 68.824
SG - Singapore 3.571
IT - Italia 2.214
DE - Germania 1.865
CN - Cina 1.631
BR - Brasile 1.038
UA - Ucraina 910
HK - Hong Kong 879
IE - Irlanda 748
RU - Federazione Russa 602
GB - Regno Unito 527
FR - Francia 339
VN - Vietnam 330
KR - Corea 312
FI - Finlandia 260
SE - Svezia 200
NL - Olanda 159
IN - India 147
CA - Canada 141
JP - Giappone 104
PL - Polonia 101
AR - Argentina 81
ID - Indonesia 77
AT - Austria 75
MX - Messico 75
ES - Italia 72
BD - Bangladesh 70
ZA - Sudafrica 62
TR - Turchia 55
EG - Egitto 47
IR - Iran 43
BE - Belgio 39
IQ - Iraq 39
AU - Australia 37
EC - Ecuador 37
UZ - Uzbekistan 37
PK - Pakistan 36
PH - Filippine 31
CH - Svizzera 23
PE - Perù 23
CO - Colombia 22
CZ - Repubblica Ceca 22
TH - Thailandia 22
VE - Venezuela 18
MA - Marocco 17
MY - Malesia 17
CL - Cile 16
LT - Lituania 16
IL - Israele 15
RO - Romania 15
EU - Europa 14
PY - Paraguay 14
SA - Arabia Saudita 14
DO - Repubblica Dominicana 12
AE - Emirati Arabi Uniti 11
TN - Tunisia 11
TW - Taiwan 11
JO - Giordania 8
UY - Uruguay 8
A2 - ???statistics.table.value.countryCode.A2??? 7
KG - Kirghizistan 7
LB - Libano 7
PT - Portogallo 7
AL - Albania 6
AZ - Azerbaigian 6
DK - Danimarca 6
GR - Grecia 6
RS - Serbia 6
SN - Senegal 6
BG - Bulgaria 5
CR - Costa Rica 5
KE - Kenya 5
KZ - Kazakistan 5
NG - Nigeria 5
NP - Nepal 5
PS - Palestinian Territory 5
BJ - Benin 4
BO - Bolivia 4
HN - Honduras 4
JM - Giamaica 4
LU - Lussemburgo 4
NO - Norvegia 4
NZ - Nuova Zelanda 4
SK - Slovacchia (Repubblica Slovacca) 4
BA - Bosnia-Erzegovina 3
BH - Bahrain 3
DZ - Algeria 3
HU - Ungheria 3
LK - Sri Lanka 3
MD - Moldavia 3
QA - Qatar 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
AO - Angola 2
BB - Barbados 2
BY - Bielorussia 2
DM - Dominica 2
EE - Estonia 2
GA - Gabon 2
GE - Georgia 2
Totale 86.315
Salva come PNG Salva come JPEG
Città #
Woodbridge 19.549
Wilmington 17.823
Houston 14.878
Fairfield 2.145
Singapore 1.823
Ann Arbor 1.555
Chandler 1.429
Ashburn 1.372
Hong Kong 858
Seattle 857
Jacksonville 796
Cambridge 746
Beijing 702
Dublin 690
Rome 567
Dearborn 528
Medford 495
New York 478
Dallas 367
Santa Clara 362
Los Angeles 284
Milan 254
The Dalles 242
Lawrence 231
Zhengzhou 212
Buffalo 159
Boardman 123
Council Bluffs 110
Ho Chi Minh City 107
Moscow 107
San Diego 104
Munich 101
São Paulo 90
Menlo Park 82
Mülheim 80
London 79
Redwood City 77
Brooklyn 76
Creede 69
Chicago 66
Hanoi 66
Nuremberg 66
Warsaw 66
Tokyo 64
Shanghai 63
Bologna 60
Engelhard 59
Hefei 57
Jakarta 56
Nanjing 50
Montreal 45
Redondo Beach 45
Guangzhou 44
Johannesburg 44
Orem 41
Florence 40
San Francisco 40
Stockholm 40
Toronto 40
Norwalk 39
Lappeenranta 38
University Park 37
Phoenix 36
Helsinki 34
Rio de Janeiro 34
Brussels 33
Kunming 32
Falls Church 30
Naples 30
San Jose 30
Verona 30
Atlanta 29
Boston 29
Mountain View 29
Poplar 29
Center 28
Columbus 28
Denver 28
Seoul 28
Vienna 27
Palo Alto 26
Ankara 25
Del Norte 24
Amsterdam 23
Chennai 22
Frankfurt am Main 22
Mumbai 22
North Bergen 22
Turin 21
Manchester 20
Belo Horizonte 19
Dong Ket 19
Nürnberg 19
Paris 19
Porto Alegre 19
Saint Petersburg 19
Hangzhou 18
Lima 18
Mexico City 18
Bari 17
Totale 72.729
Salva come PNG Salva come JPEG
Nome #
La leucemia mieloide acuta nell’anziano. 981
Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. 647
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 596
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 514
A microgranular variant of acute promyelocytic leukemia with atypical morpho-cytochemical features and an early myeloid immunophenotype 511
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 501
BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. 496
A novel t(11;12)(q23-24;q24) in a case of minimally-differentiated acute myeloid leukemia (AML-M0) 492
AML-M0: A review of laboratory features and proposal of new diagnostic criteria 490
An allele-specific RT-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia 481
Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation 479
CD7 expression in acute myeloid leukemia 479
All-trans-retinoic acid plus low-doses of cytarabine for the treatment of poor-risk acute myeloid leukemias 478
Minimally differentiated acute myeloid leukemia (AML-MO): a distinct clinico-biologic entity with poor prognosis 477
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 475
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes 475
Analysis of the expression of adhesion molecules on CD34+ progenitors from bone marrow, umbilical cord blood and G-CSF mobilized peripheral blood 474
A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias 466
Comparison between conventional banding analysis and FISH screening with an AML specific set of probes in 260 patients 460
Acute megakaryoblastic leukemia: experience of GIMEMA trials 459
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) 457
Biological profile of 23 cases of minimally differentiated acute myeloid leukemia (AML-MO) and its clinical implications 457
Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. 456
Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr 456
Red blood cell depletion of cord blood using hydroxyethylstarch double sedimentation: analysis of 40 cases 454
Clinical significance of CD38 expression in chronic lymphocytic leukemia 454
Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia - Analysis of prognostic factors 454
Multiparametric analysis for the enumeration of CD34+ cells from bone marrow and stimulated peripheral blood 454
Diagnosis of acute myeloid leukemia and system Coulter VCS 452
Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients 451
Leukocyte alkaline-phosphatase score in plasma-cell dyscrasias - correlation with disease severity and circulating levels of granulocyte-colony-stimulating factor 451
Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin 449
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 448
Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia 448
M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience. 447
Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia 447
Novel role of triazenes in haematological malignancies: Pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia 446
All-trans retinoic acid (ATRA) administration during pregnancy in relapsed acute promyelocytic leukemia 445
P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia 444
Biological features of acute myeloid leukemia in the elderly 444
Minimally differentiated acute myeloid leukemia (AML-MO): Comparison of 25 cases with other French-American-British subtypes 443
Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making 442
Efficacy and safety of human leucocyte interferon-alpha treatment in patients younger than 60 years of age with polycythaemia vera 441
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: Results of a randomized phase III trial of the EORTC and GIMEMA consortium (AML-17) 441
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 441
O6-(4-Bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro 440
Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia 436
Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma 434
Lecam1/Icam1 ratio identifies a distinct pattern on normal and myelodysplastic bone marrow CD34+ progenitors cells 434
P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia 432
Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). 430
Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas 429
AML-M0: a biological and clinical profile 428
CD7 Expression in acute myeloid leukemia 427
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial 427
Clinical implication of cytokine and soluble receptor measurements in patients with newly diagnosed aggressive non Hodgkin Lymphomas 424
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study 424
New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia 421
Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia 421
First report of t(8;21)(q22;q22) in a case of de novo acute monoblastic leukemia 421
Biological pattern of AML-M0 versus AML-M1: Response 421
Peripheral polyneuropathy during treatment with alpha-2 interferon 419
Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients 418
A haematology consensus agreement on antifungal strategies for neutropenic patients with haematological malignancies and stem cell transplant recipients 418
Azacitidine for the treatment of lower risk myelodysplastic syndromes : A retrospective study of 74 patients enrolled in an Italian named patient program. 417
Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data 417
Minimally differentiated acute myeloid-leukemia (aml-mo): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases 416
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia 414
Blood stem cell processing 413
Advances in the treatment of elderly and frail patients with acute myeloid leukemia 413
Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0) 412
Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage 412
Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia 411
Contribution of immunophenotypic and genotypic analysis to the diagnosis of acute leukemia 411
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 411
High interleukin-6 plasma levels in acute promyelocytic leukemia 409
Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm 409
Recurrence of a t(8;21)-positive acute myeloid leukemia in the form of a granulocytic sarcoma involving cranial bones: a diagnostic and therapeutic challenge 408
Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia 408
Fluorescence in situ hybridization and conventional cytogenetics for the diagnosis of 11q23(+)/MLL+ translocation in leukaemia 407
Red blood cell depletion and cryopreservation of umbilical cord blood (UCB) 406
P-glycoprotein expression in de novo acute myeloid leukemia 405
In vitro down-regulation of bcl-2 expression by all-trans retinoic acid in AML blasts 405
Cytogenetic and molecular diagnostic characterization combined to post-consolidation minimal residual disease assessment by flow-cytometry improves risk stratification in adult acute myeloid leukemia 404
Azacitidine for the treatment of patients with acute myeloid leukemia 404
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation 403
All-trans retinoic acid and low dose cytosine arabinoside for the treatment of "poor prognosis" acute myeloid leukemia 402
Quantitative analysis of P-glycoprotein, Bcl-2 and transferrin receptor allows the stratification of acute myeloid leukemia patients within different prognostic risk classes 402
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. 401
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia 401
Clinical heterogeneity of idiopathic CD4+T lymphocytopenia 401
Thoracic cord compression caused by epidural extramedullary hematopoiesis during erythroid-stimulating agent therapy in two patients with myelodysplastic syndromes 400
Minimally differentiated acute myeloid leukemia (AML-MO): A distinct clinico-biologic entity with poor prognosis 397
Role of human leukocyte interferon-alpha in the treatment of patients with polycythemia vera 397
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 396
NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma 395
Immunophenotypic analysis in 119 patients with acute myeloid leukemia following a previous malignancy: a comparison with the immunophenotype of 231 de novo cases 394
GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. 393
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. 391
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107) 391
Totale 44.333
Salva come PNG Salva come JPEG
Categoria #
all - tutte 209.797
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 209.797
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20214.941 0 0 0 0 0 1.182 1.460 1.053 333 324 440 149
2021/20222.677 105 308 88 102 77 247 145 164 212 234 207 788
2022/20233.950 414 306 291 410 264 754 482 242 450 70 186 81
2023/20242.238 169 81 199 81 256 551 139 142 98 72 106 344
2024/20257.094 284 1.460 787 403 194 430 548 420 745 625 576 622
2025/20266.403 1.233 624 1.641 1.060 1.351 494 0 0 0 0 0 0
Totale 87.502